Physician profile
David Kadmon
NPI 1912946658
$12,749.07
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,931 · 2020: $2,665 · 2021: $1,129 · 2022: $733 · 2023: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $290.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $6,576.36 | 2019 | |
| Ucb, INC. | $1,864.94 | 2019-2023 | Cimzia |
| Amgen INC. | $1,108.01 | 2019-2023 | Enbrel, Prolia, Evenity |
| Janssen Biotech, INC. | $750.22 | 2019-2022 | |
| Glaxosmithkline, LLC. | $724.68 | 2019-2023 | Nucala, Benlysta |
| E.R. Squibb & Sons, L.L.C. | $307.10 | 2019-2021 | |
| Horizon Therapeutics Plc | $228.00 | 2019-2021 | |
| Abbvie INC. | $199.35 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.82 | 2019-2023 | Ofev |
| Organon LLC | $156.65 | 2021-2023 | Renflexis |
| Astrazeneca Pharmaceuticals Lp | $141.28 | 2022-2023 | Saphnelo |
| Pfizer INC. | $119.85 | 2019-2021 | |
| Lilly USA, LLC | $96.98 | 2019-2023 | Taltz |
| Genentech USA, INC. | $91.79 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $70.28 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $50.94 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $42.24 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $26.21 | 2022 | |
| Bioventus LLC | $14.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kadmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.